Carsten Schwaenen

Albert Einstein Allee 23
Ulm, BW 89081, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.

Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine.

Journal: European journal of haematology
Published: May 27, 2024

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.

Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide: an international collaborative study.

Journal: Haematologica
Published: March 06, 2021

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 04, 2019

A modular transcriptome map of mature B cell lymphomas.

A modular transcriptome map of mature B cell lymphomas.

Journal: Genome medicine
Published: November 09, 2018

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Journal: Leukemia
Published: January 18, 2018

A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

A subgroup of pleural mesothelioma expresses ALK protein and may be targetable by combined rapamycin and crizotinib therapy.

Journal: Oncotarget
Published: November 26, 2017

A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.

A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.

Journal: Blood
Published: January 09, 2014

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Biological characterization of adult MYC-translocation-positive mature B-cell lymphomas other than molecular Burkitt lymphoma.

Journal: Haematologica
Published: November 02, 2013

High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.

High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas.

Journal: Genes, chromosomes & cancer
Published: June 04, 2012

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.

Patient age at diagnosis is associated with the molecular characteristics of diffuse large B-cell lymphoma.

Journal: Blood
Published: January 13, 2012

Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.

Recurrent deletions of the TNFSF7 and TNFSF9 genes in 19p13.3 in diffuse large B-cell and Burkitt lymphomas.

Journal: International journal of cancer
Published: October 10, 2011
Showing 1-11 of 11

Last Updated: 09/26/2026